Generic Depakote wins FDA approval

A generic version of Depakote, an anti-seizure medication that clinicians also use to treat migraine headaches and bipolar disorder, received FDA approval yesterday. Abbott Laboratories originally manufactured the drug.

The approval was for delayed-release tablets and will have the same black box warning that the branded drug has, which includes warnings about liver and pancreas risks, as well as the risk of birth defects. 

Eight different companies received licensure to begin marketing the drug, including Sun Pharmaceuticals and Teva Pharmaceuticals.

- here's the FDA release
- read the story at WebMD
- see more from the Washington Post

Suggested Articles

It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.